Plus Therapeutics to Present at the YAFO Access China Partnering Conference on July 30, 2020
July 23 2020 - 5:00PM
Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”) today
announced that it will be presenting at the YAFO ACCESS CHINA -
2020 Summer Online Partnering Day on Thursday, July
30 at 10:00 pm EST. Dr. Marc Hedrick, President and CEO
of Plus Therapeutics, will be hosting the presentation and
answering questions from investors.
To access the live presentation, please use the
following information:
YAFO ACCESS CHINA Partnering
Conference |
Date: |
Thursday, July
30, 2020 |
Time: |
10:00 p.m. Eastern Time (7:00 p.m. Pacific Time) |
If you would like to register for the event, you
may purchase a free Live Day Attendee Ticket or Video on Demand
Attendee Ticket here:
https://www.eventbrite.com/e/access-china-2020-summer-online-partnering-day-tickets-106868540682
If investors are unable to make the live
presentation, a replay-day will be arranged one week later and a
link will be posted to the Company’s website.
About YAFO Life Science
YAFO Life Science is the healthcare division of
YAFO Capital, a Shanghai-based investment bank boutique and
investment firm focused on Life Sciences. YAFO organizes every year
ACCESS CHINA Forum event series providing online corporate access
through its proprietary deal-making platform, which covers 2,000+
BD directors and executives from Chinese biopharma, healthcare, and
investment firms. ACCESS CHINA creates invaluable BD opportunities
by directly connecting and meeting with the right partners for
development, licensing, or commercial collaborations. Together with
its co-organizers and partners, YAFO Life Science helps Western
biopharma companies efficiently present their assets online in
front of 500+ healthcare companies and VCs in China.
About Plus Therapeutics, Inc.
Plus Therapeutics (Nasdaq: PSTV) is a
clinical-stage pharmaceutical company whose radiotherapeutic
portfolio is concentrated on nanoliposome-encapsulated
radionucleotides for several cancer targets. Central to the
Company’s drug development is a unique nanotechnology platform
designed to reformulate, deliver and commercialize multiple drugs
targeting rare cancers and other diseases. The platform is designed
to facilitate new delivery approaches and/or formulations of safe
and effective, injectable drugs, potentially enhancing the safety,
efficacy and convenience for patients and healthcare providers.
More information may be found at www.plustherapeutics.com and
at www.respect-trials.com
Contact:
Plus Therapeutics, Inc. Andrew Sims VP –
Chief Financial Officer, Investor Relations Phone: +1.619.333.4150
Email: ir@plustherapeutics.com Corporate
Website: plustherapeutics.comClinical
Website: respect-trials.com
Plus Therapeutics (NASDAQ:PSTV)
Historical Stock Chart
From Mar 2024 to Apr 2024
Plus Therapeutics (NASDAQ:PSTV)
Historical Stock Chart
From Apr 2023 to Apr 2024